← boardnext 2027-02
GNLX
Genelux Corporationdistress 4/10 · elevated risk$2.99+1%today-64% from 52w high
Oncology 1
Lead: Advanced Non-squamous Non-small-cell Lung Cancer · est. market ~$35B (approx, global)
Revenue
pre-revenue
Liquidity
$27M
Runway
1.1 yrs
Shares 1y
+19%
Price & events
+3.8% over 6M
CatalystRating changeDilutionFinancingdashed = today
+1.0%
1D
+6.0%
1W
+2.4%
1M
+18.7%
3M
+4.2%
6M
-16.9%
1Y
+38.4%
2Y
—
5Y
-51.4%
All
Overview
- Market Cap
- $134.07M
- Volume
- 47.44K
- 52 Week Range
- $2.30 – $8.24
- Total Shares
- 44.84M
- Float Shares
- 36.13M
- Short %
- 6.91%
- % Held by Insiders
- 13.12%
- % Held by Institutions
- 30.71%
- RVOL
- 0.26x
- Beta
- 0.57
Pipeline stages · 2 programs
Olvimulogene nanivacirepvec, Platinum chemotherapy: carboplatin or cisplatin, Non-platinum
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
olvimulogene nanivacirepvec, Platinum chemotherapy: carboplatin (preferred) or cisplatin, Non-platinum chemotherapy: Physician's Choice of gemcitabine, taxane (paclitaxel, docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicin, Bevacizumab (or biosimilar)
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 2 trials · 1 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2027-02 Estimated 50% readout ~2027-03-18 | Phase 2 | Olvimulogene nanivacirepvec, Platinum chemotherapy: carboplatin or cisplatin, Non-platinum | Advanced Non-squamous Non-small-cell Lung Cancer, Advanced Squamous Non-Small Cell Lung Carcinoma, Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Squamous Non-Small Cell Lung Carcinoma, Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Stage III, Non-small Cell Lung Cancer Stage IV, Non-small Cell Lung Cancer Recurrent | — | recruiting |
| 2026-06 | Phase 3 | olvimulogene nanivacirepvec, Platinum chemotherapy: carboplatin (preferred) or cisplatin, Non-platinum chemotherapy: Physician's Choice of gemcitabine, taxane (paclitaxel, docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicin, Bevacizumab (or biosimilar) | Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, High-grade Serous Ovarian Cancer, Endometrioid Ovarian Cancer, Ovarian Clear Cell Carcinoma | 186 | recruiting |
Catalyst news & presentations · 4
- throughout 2026Guided 40%readoutPhase 1/2Olvi-Vec · Additional interim data from Phase 1b/2 SCLC trialSEC 8-K
- first half of 2026readoutPhase 3Olvi-Vec · Topline results from Phase 3 OnPrime/GOG-3076 trialSEC 8-K
- second half of 2025readoutPhase 2Olvi-Vec · Interim results from Phase 2 VIRO-25 trialSEC 8-K
- 2025-03-25fda agreementOlvi-Vec · Type D meeting with FDA for PRROC; FDA agreed interim OS analysis at primary PFS could support traditional approval.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- 2026-03-20BenchmarkSpeculative Buy
- 2025-10-21Lake StreetBuy
- 2025-07-21LUCID CAPITAL MARKETSBuy
- 2025-05-08BenchmarkSpeculative Buy
- 2025-03-31HC Wainwright & Co.Buy
- 2025-03-25HC Wainwright & Co.Buy
Competitors — Advanced Non-squamous Non-small-cell Lung Cancer
- BEIGFBeOne Medicines Ltd.$31.7B · D1
Recent news
- 2026-07-02GENELUX (NASDAQ: GNLX) director sells 12,000 shares to cover RSU tax bill - Stock Titan
- 2026-07-01GENELUX Corp SEC Filing (Jul 1, 2026) - Stock Titan
- 2026-06-30Genelux says Olvi-Vec may reawaken platinum response in ovarian cancer - Stock Titan
- 2026-06-22Genelux (GNLX) 2026 meeting backs director John Smither and auditor - Stock Titan
- 2026-06-18GENELUX (NASDAQ: GNLX) director granted RSUs and options in new equity awards - Stock Titan
- 2026-06-04Genelux head of regulatory Ralph Smalling sells $562 in stock - Investing.com
- 2026-06-02Genelux director Thomas John sold $29,801 in company stock - Investing.com
- 2026-05-12Genelux president and CEO Zindrick Thomas sells $8,225 in stock - Investing.com
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.